# Korro Bio, Inc.: Phase 2 study started recruiting, 30 planned (Urea Cycle Disorders, Inborn, Urea Cycle Disorders)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Korro Bio, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD |
| NCT ID | NCT07773246 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Urea Cycle Disorders, Inborn; Urea Cycle Disorders; Ornithine Transcarbamylase (OTC) Deficiency; Arginase 1 Deficiency; NAGS Deficiency; Carbamylphosphate Synthetase I |
| Intervention types | drug |
| Target enrollment | 30 |
| Site countries | Australia |
| Posted | 2026-08-19 |
| Planned start | 2026-09-28 |
| Event | Started recruiting |
| Event date | 2026-09-28 |
| Last update posted | 2026-10-08 |

## Why this score
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07773246). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.